Related Experiment Video
Updated: Jun 17, 2026
11:47
Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
Published on: January 22, 2017
[Succinic semialdehyde dehydrogenase deficiency: decrease in 4-OH-butyric acid levels with low doses of vigabatrin].
G Iglesias Escalera1, I Ferrer, Ll Carrasco Marina
1Servicio de Pediatría, Hospital Severo Ochoa, Leganés, Madrid, España.
Anales De Pediatria (Barcelona, Spain : 2003)
|December 19, 2009
Summary
Succinic semialdehyde dehydrogenase deficiency, a rare neurometabolic disorder, causes neurological and psychiatric symptoms. Treatment with vigabatrin showed potential for reducing gamma-hydroxybutyric acid levels and improving clinical outcomes.
Area of Science:
- Neurology
- Metabolic Disorders
- Genetics
Background:
- Succinic semialdehyde dehydrogenase deficiency (gamma-hydroxybutyric aciduria) is a rare neurometabolic disorder.
- It results from impaired gamma-aminobutyric acid degradation, leading to elevated gamma-hydroxybutyric acid levels.
Observation:
- The study presents two siblings diagnosed with this condition.
- Clinical manifestations included psychomotor delay, hypotonia, and language disability.
- Elevated plasma and urine gamma-hydroxybutyric acid levels were confirmed through metabolic studies.
Findings:
- Mutation analysis of the ALDH5A1 gene confirmed the diagnosis.
- Treatment with low-dose vigabatrin in the older sibling led to decreased gamma-hydroxybutyric acid levels.
- A slow but observable clinical improvement was noted after one year of vigabatrin therapy.
Implications:
- This case highlights the diagnostic challenges and heterogeneous clinical presentation of succinic semialdehyde dehydrogenase deficiency.
- The findings suggest vigabatrin may be a viable therapeutic option, warranting further investigation into its efficacy.
- Early diagnosis and intervention are crucial for managing this rare neurometabolic disease.
Related Concept Videos
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:35Loss of Carboxy Group as CO2: Decarboxylation of Malonic Acid Derivatives
Just like β-keto acids—which upon thermal decarboxylation form ketones—β-dicarboxylic acids undergo decarboxylation to generate monocarboxylic acids with the liberation of carbon dioxide.
01:26Anticholinesterase Agents: Poisoning and Treatment
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:24Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...